Skip to content

Which Orphan Drug Companies Are Top-Performing BioTechs In 2012 ?

December 9, 2012

       Per a December 6, 2012, article, Sarepta Therapeutics was identified as one of the top-performing BioTechs in 2012. Per the article, Sarepta Therapeutics has a “Year-To-Date Performance of 512.89%” as a result of very positive clinical trial data for orphan drug Eteplirsen for the treatment of Duchenne Muscular Dystrophy. 

        Also, Celsion has a “Year-To-Date Performance of 335.88%” as a result of the anticipated release in January 2013 of clinical trial data for orphan drug ThermoDox for the treatment of Hepatocellular Carcinoma.  

         The article ends by identifying Exelixis as the BioTech to watch in 2013. Exelixis’ orphan drug Cometriq received FDA approval last week to treat Medullary Thyroid Cancer (MTC). Exelisis plans on expanding Cometriq for future treatment of additional  cancer indications. 

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: